JOIN OUR COMMUNITY

Europe

View All
Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30
July 13, 2026 0

Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30

By Dino Mustafić

Poolbeg Pharma (AIM: POLB) said on 13 July that the first patient has been dosed in its POLB 001 TOPICAL trial, according to the company's RNS statement, and that University...

The Rerouting of Europe‘s medicine cabinet: How the Iran war is reshaping pharmaceutical supply chains

April 20, 2026 Off
Faron’s €40 million lifeline: fully covered, but shareholders have weeks to decide

Faron’s €40 million lifeline: fully covered, but shareholders have weeks to decide

March 11, 2026 Off

USA

View All
Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention
March 11, 2026 Off

Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention

By Dino Mustafić

A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

GSK purchases 35Pharma for $950M to expand into pulmonary hypertension

February 26, 2026 Off
BMS, Bain Capital create new company to focus on therapies for autoimmune diseases

BMS, Bain Capital create new company to focus on therapies for autoimmune diseases

July 29, 2025 Off

My Pharmaceutical

View All
BioCardia’s cell therapy may help the failing heart stop working against itself
March 13, 2026 Off

BioCardia’s cell therapy may help the failing heart stop working against itself

By Dino Mustafić

Phase III echocardiography data presented at THT 2026 suggest a targeted cellular approach may do what drugs alone cannot for a specific population of ischemic heart failure patients

Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention
March 11, 2026 Off

Light instead of antibiotics: Ondine’s Phase 3 trial is weeks away from results that could reshape surgical infection prevention

By Dino Mustafić

A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according...

AI and job cuts: What the block layoffs signal for pharma and beyond
February 27, 2026 Off

AI and job cuts: What the block layoffs signal for pharma and beyond

By Dino Mustafić

In the past few months, the corporate world has seen a surge in workforce reductions that are explicitly tied to...




Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30
July 13, 2026 0

Poolbeg doses first patient in its CRS prevention trial, but the real test is n=30

By Dino Mustafić

Poolbeg Pharma (AIM: POLB) said on 13 July that the first patient has been dosed in its POLB 001 TOPICAL trial, according to the company’s RNS statement, and that University College London Hospital has now also been activated as a clinical trial site, with additional sites expected to open imminently. Investor reaction will hinge less on the milestone itself — dosing a first patient is table stakes for any trial — and more on what happens over the next six to eight weeks, since interim data is still on track for late summer.